Investing.com - Financial Markets Worldwide

Immunomedics Inc (IMMU)

NASDAQ
Symbol
Exchange
Currency
87.86
0.00(0.00%)
-Closed.
Currency in USD
  • Volume:
    0
  • Day's Range:
    87.59 - 87.93
  • 52 wk Range:
    87.59 - 87.93

IMMU Overview

Prev. Close
87.86
Day's Range
87.59-87.93
Revenue
20.36M
Open
87.85
52 wk Range
87.59-87.93
EPS
-1.72
Volume
0
Market Cap
20.32B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
3,024,485
P/E Ratio
-
Beta
2.58
1-Year Change
0%
Shares Outstanding
231,320,559
Next Earnings Date
-
What is your sentiment on Immunomedics?
or
Market is currently closed. Voting is open during market hours.

Immunomedics Inc News

Immunomedics Inc Analysis

Immunomedics Inc Company Profile

Immunomedics Inc Company Profile

Industry
Biotechnology
Sector
Healthcare
Employees
0
Market
United States

Immunomedics, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibody-based products to treat cancer. The company develops sacituzumab govitecan, an antibody-drug conjugate for the treatment of patients with metastatic triple-negative breast cancer. It focuses on commercializing sacituzumab govitecan as a third-line therapy for patients with metastatic triple-negative breast cancer in the United States. The company also develops IMMU-140 for the treatment of hematologic malignancies; and IMMU-130 to treat Colorectal cancer. Its other product candidates includes epratuzumab, an anti-CD22 antibody; veltuzumab, an anti-CD20 antibody; milatuzumab, an anti-CD74 antibody; and IMMU-114, a HLA-DR antibody. The company has clinical collaboration with AstraZeneca and MedImmune to evaluate Imfinzi, a human monoclonal antibody against PD-L1, with sacituzumab govitecan as a frontline treatment of patients with TNBC and urothelial cancer; collaboration agreement with GBG Forschungs GmbH to develop sacituzumab govitecan for the treatment of breast cancer; and clinical collaboration with F. Hoffman-La Roche Ltd to treat patients with metastatic or inoperable locally advanced TNBC versus atezolizumab plus nab-paclitaxel as standard of care. The company was incorporated in 1982 and is headquartered in Morris Plains, New Jersey. As of October 23, 2020, Immunomedics, Inc. operates as a subsidiary of Gilead Sciences, Inc.

Read More

Income Statement

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellNeutralBuyStrong BuyStrong Buy
Technical IndicatorsSellBuyStrong BuyStrong BuyStrong Buy
SummarySellNeutralStrong BuyStrong BuyStrong Buy

Trending Stocks

Trending Stocks

Name
Last
High
Low
Chg.
Chg. %
Vol.
Time
AMD
92.6593.8989.52+1.49+1.63%109.22MNASDAQ
Stryker
235.01236.58231.02+1.73+0.74%1.11MNYSE
Artisan Acquisition Corp
5.225.535.07+0.14+2.76%55.18KNASDAQ
NextEra Energy
74.7975.1573.59+0.12+0.16%11.18MNYSE
Canadian Pacific Railway
68.3968.6867.41-0.19-0.28%1.76MNYSE
Alibaba ADR
82.3184.0781.07-0.16-0.19%22.86MNYSE
Ginkgo Bioworks
2.882.882.56+0.300+11.63%22.53MNYSE
Newtek
23.5523.8523.17+0.10+0.43%290.04KNASDAQ
Stran
2.162.221.92+0.17+8.54%577.31KNASDAQ
Innovative Solutions
8.718.958.71-0.190-2.13%13.36KNASDAQ
Schlumberger
45.0545.3143.57+1.15+2.62%17.10MNYSE
Broadcom
531.63537.45523.90+7.43+1.42%1.76MNASDAQ
Cummins
202.62203.51195.87+6.11+3.11%1.13MNYSE
Lava Medtech Acquisition Unt
10.0310.039.920.000.00%0.00NASDAQ
Aethlon Medical Inc
1.281.4981.20-0.180-12.33%802.30KNASDAQ
  • I bought 300 shares under 85 and cashed out today at $87.56. Since I was in the margin made sense for me to forgo $132 and take the $800 profit.
    1
    • if I buy this share at current price@85 ... what will happen to my shares after the merge? my shares will be converted to gilead shares at what every price let say $65 + $88? so one share will be let say the current immu price $85- let say gilead$65 + 88? one share will be $153 instead of 173.does the symbol changes to gilead?
      0
      • You will receive $88 cash for each share you hold. I don't think you'll receive Gilead shares.
        0
    • 🕷️ spider run run ... market crash is coming
      1
      • I bought 200 shares at $84.64. Can't walk away from a 3.8% gain, even if I have to wait a month or two.
        0
        • I believe it's a good move. Thinking about the same thing. Of course the only risk is the acquisition deal falling through (for whatever reason). In that unlikely case this would go back to $40-50 range.
          0
        • Jim HerbertDoubt it. Both boards approved it unanimously.
          0
      • Seems this will drop now
        0
        • Why really though? They are being acquired for $88 per share. Why would any shareholder sell significantly below that? There can be one reason: Betting on the acquisition decision by Gilead changing and it not happening eventually.
          1
      • Why is this stuck?
        0
        • Well, Gilead is gonna acquire them for $88 per share. So all shareholders will get $88 for each share they are holding. Currently why would anyone pay more than $88? Similarly, why would anyone sell it for less than $88? It should be stuck near $88 until the acquisition actually takes place in my opinion. Is this not the logic?
          0
      • 50 by friday hold tight going doen to china-town!!
        0
        • I put for put on it for like little 40 all 4 cast that I'm already up like 400 already but still I stand to lose 40 and to gain a couple 1000s so I'm good with that
          1
          • in my opinion anyone why buy this today good luck because you see how all this month been from it start one minute the market is up then next it's not so I wouldn't dare jump in on a buy worse it's the first of it jumping up
            0
            • Law of gravity: What goes up must come down.
              1